Opko Health Inc. (NASDAQ:OPK) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 81,261,939 shares, a growth of 10.1% from the February 28th total of 73,801,069 shares. Based on an average trading volume of 5,628,579 shares, the short-interest ratio is currently 14.4 days. Currently, 22.6% of the shares of the company are sold short.
A number of brokerages have weighed in on OPK. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a report on Monday, February 4th. Barrington Research reissued a “buy” rating and issued a $5.00 price target on shares of Opko Health in a report on Thursday, February 28th. Finally, ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and an average target price of $9.67.
In other Opko Health news, Vice Chairman Jane Ph D. Hsiao purchased 10,000 shares of the business’s stock in a transaction on Thursday, January 31st. The stock was bought at an average cost of $7.96 per share, with a total value of $79,600.00. Following the acquisition, the insider now owns 24,455,147 shares of the company’s stock, valued at $194,662,970.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Phillip Md Et Al Frost purchased 50,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The stock was acquired at an average cost of $2.42 per share, with a total value of $121,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $7,426,861.42. The disclosure for this purchase can be found here. Insiders have bought 798,000 shares of company stock valued at $2,032,580 in the last 90 days. Insiders own 42.74% of the company’s stock.
NASDAQ OPK traded down $0.01 on Friday, hitting $2.40. 6,731,012 shares of the company were exchanged, compared to its average volume of 3,690,665. The company has a current ratio of 1.10, a quick ratio of 0.96 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.48 billion, a PE ratio of -9.60 and a beta of 1.88. Opko Health has a twelve month low of $2.34 and a twelve month high of $6.40.
Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The firm had revenue of $221.90 million for the quarter, compared to the consensus estimate of $242.05 million. Opko Health had a negative return on equity of 7.69% and a negative net margin of 15.46%. Research analysts forecast that Opko Health will post -0.2 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Short Interest in Opko Health Inc. (NASDAQ:OPK) Expands By 10.1%” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/21/short-interest-in-opko-health-inc-opk-expands-by-10-1.html.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.